Product
Tebentafusp with Pembrolizumab
Aliases
tebentafusp, Tebentafusp
Name
KIMMTRAK
FDA Approved
Yes
1 clinical trial
1 organization
2 drugs
1 indication
1 document
Indication
MelanomaDrug
tebentafuspDrug
AdagrasibClinical trial
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)Status: Recruiting, Estimated PCD: 2026-12-01
Document
DailyMed Label: KIMMTRAKOrganization
Immunocore Commercial LLC